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Abstract
Purpose To assess the role of clinical, biochemical, and morphological parameters, as added to cytology, for improving pre-
surgical diagnosis of palpable thyroid nodules.
Methods Patients with a palpable thyroid nodule were eligible if surgical intervention was indicated after a positive or
suspicious for malignancy FNAC (TIR 4–5 according to the 2007 Italian SIAPEC-IAP classiﬁcation), or two inconclusive
FNAC at a ≥3 months interval, or a negative FNAC associated with one or more risk factor. Reference standard was
histological malignancy diagnosis. Likelihood ratios of malignancy, sensitivity, speciﬁcity, negative (NPV), and positive
predictive value (PPV) were described. Multiple correspondence analysis (MCA) and logistic regression were applied.
Results Cancer was found in 433/902 (48%) patients. Considering TIR4–5 only as positive cytology, speciﬁcity, and PPV
were high (94 and 91%) but sensitivity and NPV were low (61 and 72%); conversely, including TIR3 among positive,
sensitivity and NPV were higher (88 and 82%) while speciﬁcity and PPV decreased (52 and 63%). Ultrasonographic size
≥3 cm was independently associated with benignity among TIR2 cases (OR of malignancy 0.37, 95% CI 0.18–0.78). In
TIR3 cases the hard consistency of small nodules was associated with malignity (OR: 3.51, 95% CI 1.84–6.70, p < 0.001),
while size alone, irrespective of consistency, was not diagnostically informative. No other signiﬁcant association was found
in TIR2 and TIR3.
Conclusions The combination of cytology with clinical and ultrasonographic parameters may improve diagnostic deﬁnition
of palpable thyroid nodules. However, the need for innovative diagnostic tools is still high.
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Introduction
The discovery rate of thyroid nodules has widely risen in
last decades, mainly due to the detection of clinically
unapparent lesions by means of ultrasonography (US) [1].
This clearly emerged by an old prospective study compar-
ing palpation and US in a population of subjects without
known thyroid disease [2]. Authors reported an US pre-
valence as high as 67%, whereas palpable nodules were
detected in only 21% of the cohort. However, the actual
clinical utility of discovering such a quantity of non-
palpable nodules seems to be poor as the risk of malignancy
is negligible [3]. Palpable thyroid nodules are reported in
approximately 4–7% of the population [4, 5]. In this setting,
the rate of malignancy is more relevant, being estimated
from 8 to 16% [6, 7]. Therefore, palpable thyroid lesions
may be considered as a separate clinical entity requiring a
speciﬁc diagnostic approach.
To date, several guidelines on the management of thyroid
nodules have been published, but a clear distinction
between palpable and non palpable lesions has never been
performed [6, 8–14]. Furthermore, a number of clinically
relevant topics are still debated, and need to be addressed by
additional studies. The areas of uncertainty concerns, for
instance, the use of ultrasound scan criteria to assess cancer
risk, the indication for ﬁne-needle aspiration cytology
(FNAC), the new diagnostic and therapeutic techniques,
including molecular markers, and the optimal follow-up
strategy for patients with benign thyroid nodules.
The evaluation of thyroid nodules includes clinical
examination, ultrasound, ﬁne needle aspiration cytology.
Currently, FNAC is considered the most accurate test, for
evaluation of thyroid nodule due to the high sensitivity
(83%) and speciﬁcity (92%) [15, 16].
The available literature about the diagnostic accuracy of
FNAC, however, is based almost exclusively on retro-
spective studies performed in cases of positive or inde-
terminate cytology. Currently, only patients with positive
FNAC undergo surgery, thus, for the majority of cases with
negative cytology, a histological correlation is not available.
The question of false negatives is addressed in several
studies [8, 17–23]. A rate of 25% of false negatives has
been reported. Importantly, this percentage is even higher in
large palpable nodule (≥4 cm) [17, 24]. This suggests that
FNAC sensitivity may be even more limited in the setting of
palpable nodules, where up to a third of cases of malig-
nancy may be missed [22].
Aim of the present study is to assess the role of clinical,
biochemical, and morphological parameters as auxiliary
tools, added to cytology, for improving pre-surgical diag-
nosis of palpable thyroid nodules.
Materials and methods
Study design
We performed a multicentre prospective observational
study to describe the predictive value for diagnosis of
malignancy of several clinical, laboratory and radiological
parameters, commonly measured in routine clinical practice.
The study protocol was approved by the ethical committees
at all participating Institutions. Patients were consecutively
enrolled at seven participating centers.
Study population
Patients ≥18 years old were eligible if they had a palpable
thyroid nodule, for which surgical intervention was indi-
cated. In details, surgery was indicated when at least one of
the following three conditions was present: (1) cytological
examination positive or suspicious of malignancy (TIR 4-5
according to the 2007 Italian SIAPEC-IAP classiﬁcation
[25]), (2) two inconclusive cytological examinations with a
≥3 months interval, (3) cytological examination negative for
malignant cells (TIR 2-3) associated with at least one major
and two minor risk criteria. Major and minor risk criteria
were arbitrarily deﬁned by the study protocol. Major risk
criteria included clinical (previous neck irradiation), bio-
chemical (calcitonin levels more than twice the upper nor-
mal value in absence of renal failure and of pump inhibitors
use or positivity at the pentagastrin stimulation test) or
ultrasonographic (hypoechogenicity, irregular margins,
major diameter ≥3 cm, microcalciﬁcations). Minor risk cri-
teria included clinical (hard consistency of the nodule, age
>45, male gender), biochemical (human thyreoglobulin
[HTG] > 2000 ng/ml) or ultrasonographic (increase of the
major diameter in patients on treatment with thyroxine
≥5 mm if previous diameter was <1 cm or ≥1 cm if previous
diameter was ≥1 cm, intranodular vascularization at Doppler
examination).
Patients were excluded in case of concomitant diseases
preventing surgery, evidence of locally advanced disease or
metastases (lymph nodes or other distant sites). Also
patients with non-palpable nodes were excluded. Informed
consent was obtained from all individual participants
included in the study.
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Study procedures
Eligible patients underwent FNAC and surgery, indepen-
dently of the result of cytology. Ultrasonographic evalua-
tion was performed according to participating center
practice by experienced radiologists and no independent
conﬁrmation was mandated by the protocol.
Cytology interpretation was based on the 2007 Italian
SIAPEC-IAP 5-category scale: TIR1: non-diagnostic,
inadequate (smears should contain 6 or more groups of at
least 10 thyroid follicular cells to be considered adequate);
TIR2: benign (consistent with nodular goiter or thyroiditis);
TIR3: indeterminate; TIR4: suspicious of malignancy;
TIR5: malignant [25]. Palpable nodules >2 cm or containing
microcalciﬁcations had to be sampled with at least two
needle passes. Samples with macroscopic blood con-
tamination had to be repeated immediately, when feasible
[26, 27]. There was no independent revision of cytological
and histological diagnosis, according to a pragmatic
approach, considering that all participating centers are
considered as referral Institutions for thyroid cancer.
Statistical analysis
Diagnostic performance of FNAC was assessed using
likelihood ratio (LR), sensitivity, speciﬁcity, negative pre-
dictive value (NPV), and positive predictive value (PPV);
for all the estimated 95% conﬁdence intervals were calcu-
lated. Reference standard was histological diagnosis
(malignant/benign). Three categories of FNAC were used
(TIR2, TIR3, and TIR4-5). LR was estimated for each
FNAC category. Since the other measures of accuracy
(sensitivity, speciﬁcity, PPV and NPV) can only be calcu-
lated with dichotomous tests, we estimated them twice,
considering as positive in turn either TIR4 and TIR5 cate-
gories (TIR4-5) or the previous ones combined with the
TIR3 category (TIR3-4-5).
Associations of clinical, biochemical and ultrasono-
graphic variables with malignancy were separately eval-
uated in patients with TIR2 and TIR3 categories. Surgery
indeed was mandatory in patients with TIR4 or TIR5
cytological diagnosis and any further information would be
irrelevant for clinical decision.
Univariate associations were tested using Pearson’s chi-
square test and Fisher’s exact test, as appropriate. Multi-
variable analyses were performed by means of multiple
logistic regression models.
Since the six ultrasonographic variables were expected to
be highly correlated, relationships between them were pre-
liminary investigated with multiple correspondence analysis
(MCA) [28]. MCA is a graphical technique that allows to
display categories of variables as points in a geometric map
of relationship. The plot axes indicate latent variables that
are derived from the contribution of the single variables.
Proximities of categories in the two-dimensional plot sug-
gest possible associations between them. As a general rule
the distance between two points may be roughly interpreted
as the correlation among them although ﬁndings must also
be read in the light of the quantitative contributions of the
categories to the axes (η2). The percentage of information
explained (i.e., the percentage of total variability explained
by the two axes of the plot) was measured following Ben-
zécri: higher the percentage better the two-dimensional
representation of data [29]. To improve the interpretation of
results, the two histology categories (malignant/benign)
were depicted on the MCA plot as supplementary variables
(i.e., they did not contribute to the axes). As a result of the
exploratory MCA the six ultrasonographic variables were
combined in two new variables that were entered as cov-
ariates in the logistic models.
For all analyses, results were considered statistically
signiﬁcant if the two-tailed p-value was 0.05 or less. All
analyses were performed with R software, version 3.0.0
[The R Foundation for Statistical Computing 2013].
Results
Overall 914 eligible patients were enrolled at seven centers
between March 2010 and April 2012. Twelve patients
underwent surgery because of two consecutive inconclusive
cytological examinations; these patients were excluded
from subsequent analysis. Baseline characteristics of the
remaining 902 patients are reported in Table 1. Patients
were prevalently females (76%) with a median age of 49
years. Biochemical variables were found positive in a very
small number of patients (23 cases overall). FNAC cate-
gories were evenly distributed in the study patients (33%
TIR2, 35% TIR3 and 32% TIR4-5). A malignant tumor was
present in 48% of patient, mostly as papillary carcinoma
(86%).
Estimated LRs for each TIR category are reported in
Table 2. As expected the two extreme categories (TIR4-5
and TIR2) provided stronger information for or against
malignancy, respectively, while the intermediate category
(TIR3) was less informative. To estimate the other measures
of accuracy (Table 3) two 2 × 2 contingency tables were
derived where the intermediate category TIR3 was alter-
natively considered negative (and pooled with TIR2) or
positive (and pooled with TIR4-5). When a “positive” result
was limited to TIR4-5 category, sensitivity was equal to
61% (i.e., there was a false negative rate of 39%) and
speciﬁcity was equal to 94%, meaning that only 6% of false
positive patients were found. Accordingly PPV was high.
Conversely, when the indeterminate TIR3 category was
combined with TIR4-5 in the deﬁnition of ‘positive’ result,
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sensitivity increased to 88% (i.e., 12% of patients with
malignancy were found negative), but speciﬁcity decreased
to an unacceptably value of 52%, meaning that 48%
patients without malignancy were found positive. Accord-
ingly PPV value was only 63%.
Results of univariate analyses are summarized in the
supplementary Table online separately for FNAC negative
(TIR2) and indeterminate (TIR3) subjects. In the
TIR2 subjects, size ≥ 3 cm was signiﬁcantly associated with
the absence of malignancy while no statistically signiﬁcant
association was found for any other variable. Within the
TIR3 category, three variables were found to be associated
with histology: hard consistency at palpation and irregular
margins were more frequent in presence of malignancy
while again size ≥ 3 cm was more frequently observed when
malignancy was absent. Because of the very small pre-
valence, biochemical variables and previous neck irradia-
tion were no further evaluated in multivariate analyses.
Exploratory MCA was performed separately in FNAC-
TIR2 and FNAC-TIR3 patients. MCA two-dimensional plot
in TIR2 patients is depicted in Fig. 1. The ﬁrst two axes
accounted for 83% of the total variability. The ﬁrst axis
could be mainly interpreted as expression of morphological
modiﬁcations since it was associated with irregular margins,
hypoechogenicity, intranodular vascularization and micro-
calciﬁcations (η2 equal to 0.67, 0.52, 0.53, 0.29, respec-
tively). The second axis was strongly associated only with
size (η2= 0.83). The histology categories, plotted as sup-
plementary variables, were only slightly correlated with the
second axis. Following this exploratory analysis, tumor size
remained as single variable and a new ultrasonographic
variable was derived, morphological modiﬁcations, sum-
ming up the categories on the same side along the ﬁrst axis
(presence of irregular margins, hypoechogenicity, intra-
nodular vascularization, and microcalciﬁcations). These two
ultrasonographic variables were entered into the logistic
model as covariates.
MCA two-dimensional plot in TIR3 patients is depicted
in Fig. 2. The ﬁrst two axes accounted for 68% of the total
variability. The two axes may be read as above, and the ﬁrst
axis was associated with irregular margins, hypoechogeni-
city, intranodular vascularization and microcalciﬁcations (η2
equal to 0.55, 0.38, 0.48, and 0.38, respectively). As above,
Table 1 Baseline characteristics of the study patients
Variable N= 902
Age at diagnosis years, median (range) 49 (18–87)
Clinical variables
Previous neck irradiation 5 (1%)
Hard consistency at palpation 428 (47%)
Age > 45 years 553 (61%)
Male gender 213 (24%)
Biochemical variables
Serum calcitonin level > 2 UNL 12 (1%)
Positive pentagastrin stimulation test 3 (0%)
Serum thyreoglobulin > 2000 ng/ml 8 (1%)
Ultrasonography variables
Hypoechogenicity 719 (80%)
Irregular margins 348 (39%)
Size ≥ 3 cm 428 (47%)
Microcalciﬁcations 379 (42%)
Increase in nodule volume 216 (24%)
Intranodular vascularization 624 (69%)
Fine-needle aspiration category
TIR2 295 (33%)
TIR3 315 (35%)
TIR4-5 292 (32%)
Malignant histology 435 (48%)
Papillary carcinoma 374 (41%)
Follicular carcinoma 46 (5%)
Anaplastic carcinoma 5 (1%)
Medullary carcinoma 8 (1%)
Missing 2 (0%)
City of the participating center
Terni 210 (23%)
Taormina 196 (22%)
Roma 124 (14%)
Napoli 114 (13%)
Cagliari 108 (12%)
Padova 81 (9%)
Firenze 69 (8%)
Table 2 Diagnostic accuracy of ﬁne-needle aspiration (FNA) category
Histology
FNA category Malignant Benign Total LR (CI 95%)
TIR2 53 242 295 0.23 (0.18–0.31)
TIR3 116 199 315 0.63 (0.52–0.76)
TIR4-5 266 26 292 10.98 (7.5–16.08)
Total 435 467 902
Likelihood ratios for malignancy
Table 3 Sensitivity, speciﬁcity and predictive values for malignancy
(95% conﬁdence intervals)
Deﬁnition of test
outcome
Sensitivity Speciﬁcity PPV NPV
Positive: TIR4-5
Negative: TIR2-3
61%
(56–66%)
94%
(92–96%)
91%
(87–94%)
72%
(69–76%)
Positive: TIR3-4-5
Negative: TIR2
88%
(84–91%)
52%
(47–56%)
63%
(59–67%)
82%
(77–86%)
PPV positive predictive value, NPV negative predictive value
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size was associated with the second axis (η2= 0.78). Fol-
lowing this exploratory analysis, the same two ultrasono-
graphic variables were entered into the logistic model as
covariates.
Results of the logistic regression analyses are reported in
Table 4. The new variable “morphological modiﬁcations”,
ranging from 0 to 4, was entered in the models as a con-
tinuous covariate. As for TIR2 cases, only size ≥ 3 cm was
statistically associated with benign tumor (OR 0.37, 95% CI
0.18–0.78, p= 0.008). As for TIR3 cases, interaction
between consistency and size was statistically signiﬁcant (p
= 0.028), therefore we entered into the model three dummy
variables of combinations of consistency and size; soft
consistency and size <3 cm was the reference category. It
appeared that hard consistency combined with small size
(<3 cm) was a strong predictor of malignancy (OR 3.51,
95% CI 1.84–6.70, p < 0.001), while the other two
categories were not statistically signiﬁcant. For a better
understanding the distribution of malignant histology
according to combination of size and consistency at pal-
pation is reported in Table 5. The subgroup with the higher
percentage of malignancy is the one with hard consistency
at palpation and low nodule size.
Discussion
To the best of our knowledge, this is the ﬁrst study speci-
ﬁcally focusing on palpable thyroid nodules, considered as
a separate clinical entity, and trying to provide speciﬁc
indications about the diagnostic work-up of this clinical
setting.
A crucial feature of our paper is that the study population
included patients with palpable thyroid nodules who meet
surgical criteria, including both cytology results and clinical
parameters considered as risk factors of malignancy. This
Fig. 2 Multiple correspondence (MCA) two-dimensional plot in TIR3
patients
Table 4 Logistic regression analysis
OR 95% CI p-value
TIR2
Hard consistency at palpation 1.16 0.58–2.29 0.678
Age > 45 years 0.66 0.34–1.28 0.216
Male gender 1.55 0.76–3.16 0.224
Morphological modiﬁcationsa 1.07 0.81–1.41 0.630
Size ≥ 3 vs. <3 0.37 0.18–0.78 0.008
TIR3
Hard consistency and size <3 cm vs. soft
consistency and size <3 cm
3.51 1.84–6.70 <0.001
Soft consistency and size ≥ 3 cm vs. soft
consistency and size <3 cm
0.74 0.39–1.40 0.357
Hard consistency and size ≥ 3 cm vs. soft
consistency and size <3 cm
0.79 0.35–1.76 0.563
Age > 45 years 0.91 0.55–1.51 0.719
Male gender 1.22 0.71–2.10 0.470
Morphological modiﬁcationsa 1.26 0.99–1.59 0.056
aSum of hypoechogenicity, irregular margins, microcalciﬁcations, and
intranodular vascularization (range 0–4)
bold signiﬁcants to p-values
Table 5 Distribution of deﬁnitive histology by combination of
consistency and size of the nodule in TIR3 cases
Histology
Malignant Benign
Hard consistency and size <3 cm 40 (68%) 19 (32%)
Hard consistency and size ≥3 cm 16 (33%) 29 (67%)
Soft consistency and size <3 cm 34 (31%) 77 (69%)
Soft consistency and size ≥3 cm 20 (27%) 55 (73%)
Total 116 (37%) 199 (63%)
Fig. 1 Multiple correspondence (MCA) two-dimensional plot in TIR2
patients
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explains why nearly a half of the study subjects, therefore
much more than expected from a general cohort of patients
with palpable nodules, were diagnosed with malignant
disease at histology. By contrast, this also means that more
than a half of patients advised to surgery basing on a pre-
surgical cancer risk assessment actually harbor benign dis-
ease, thus indicating that current management of palpable
thyroid nodules needs to be improved. Another relevant
consequence of the composition of the cohort is that the
study cannot provide information about FNAC accuracy, as
taken alone. Indeed, only those subjects with benign
cytology carrying clinical risk factors of malignancy have
been included, and this represents a bias.
Therefore, the main aim of the study was to verify the
diagnostic accuracy, as deﬁned by the capability of identi-
fying patients with cancer, of the combination between
cytology and clinical parameters. Methodologically, a cru-
cial point was the deﬁnition of ‘positive’ cytological result.
Indeed, the TIR3 category is by deﬁnition a gray zone.
Furthermore, the recently introduced TIR3 subcategories
are not available as still not used in clinical practice at the
time of the study, and this represents a limit of our analysis
[30–32]. We therefore performed 2 separate analyses con-
sidering the TIR3 cytology as a negative (together with
TIR2) and positive (together with TIR 4-5) result, respec-
tively (Table 3.) When considering TIR 2-3 as the negative
cytological result, the sensitivity was only 61%, which
means that nearly 40% of malignant tumors were missed.
By contrast, when TIR2 alone was considered as the only
negative cytological category, the sensitivity rose to 88%,
determining a negative predictive value of 82%. This means
that the combination between TIR2 cytology and pre-
surgical clinical assessment, as performed in this protocol,
was related to a false negatives rate of only 12%, which was
far more less than expected basing on literature data (as
previously indicated).
In order to characterize speciﬁc diagnostic impact of the
assessed clinical variables, we analyzed the relationship of
each of them with ﬁnal histology into the categories TIR2
and TIR3, as for TIR4-5 ones surgery is mandatory and any
further information would be irrelevant for clinical deci-
sions. Around 38% of cases categorized as TIR2 or TIR3
actually had cancer, consistent with some literature claims
[22].
In both TIR2 and three categories, an independent rela-
tionship was found between large nodule size and benign
histology. This implies that the likelihood of malignancy
decreased in those palpable nodules with TIR2-3 cytology
when the diameter is ≥3 cm. Therefore, basing on previous
analysis, a TIR2 cytology from a large palpable nodule is
related to low risk of false negativity. However, our ﬁnding
that large tumors are associated with a lower risk of
malignancy is not consistent with some reports that might
be inﬂuenced by the fact only a subset of patients underwent
preoperative FNAC [33, 34].
In the TIR3 category, hard consistency at palpation in
small nodules was associated with malignancy and this may
represent a useful indication for the management of palp-
able nodules with indeterminate cytology letting clinicians
to choose thyroidectomy instead of follow-up.
The major strength of the present study is that the sample
size is quite large, as derived from institutions with a high
volume and high experience in the management of thyroid
cancer, collected prospectively, and with deﬁnitive histo-
logical examination as gold standard for deﬁnition of per-
formance of FNAC.
This study has, of course, also several limitations. As
aforementioned, our population is not representative of the
whole population of patients with palpable thyroid nodules,
because only patients for whom surgery was indicated were
included. As aforementioned, the recently introduced
TIR3 subcategories were not used. Another issue is repre-
sented by the concordance between different pathologists
[35]. Finally, inter-observer variability may also potentially
affect ultrasonography [36].
In conclusion, the combination between cytology and
assessment of clinical parameters (including clinics and US
ﬁndings) represents a feasible diagnostic approach for
palpable thyroid nodules. However, the need for innovative
diagnostic tools for malignancy, driving decision making in
clinical practice, is still high.
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